comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 17:21:40 - browse：9369

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Health insurers say they are turning to AI to cut costs, improve care

hotspot

WSS

Report: NIH

When waiting feels immoral: Empathy in the emergency department

2 officers injured in shooting in Orlando, police say

Heart disease in astronauts blamed on cosmic radiation

David Sabatini, ex

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

leisure time

comprehensive

hotspot

Medicare details structure of new drug price negotiation program

Akili, maker of video game for ADHD, to be acquired for 34 million

United colonoscopy coverage change 'may cost lives,' doctors say

2 officers injured in shooting in Orlando, police say

As demand for Covid shots wanes, Moderna seeks its next success

Adam's Biotech Scorecard: Do Sarepta's exon

Activists slam private health insurers over coverage restrictions

Scientists successfully use ultrasound imaging to map brain activity

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biohaven protein

hotspot

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Study links childhood stress with decline in older age

Do more moles mean more problems? Not so, says new study

2 officers injured in shooting in Orlando, police say

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

FDA scientists endorse Pfizer/BioNTech Covid

hotspot

focus

hotspot

Wikipedia